Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 1
1993 1
1994 3
1995 2
1996 1
1997 4
1998 2
1999 3
2000 2
2001 1
2002 2
2004 1
2005 3
2006 3
2007 2
2008 1
2009 3
2010 4
2011 3
2012 7
2013 6
2014 3
2015 8
2016 3
2017 4
2018 4
2019 6
2020 8
2021 5
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Wells SA Jr, et al. Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335. Thyroid. 2015. PMID: 25810047 Free PMC article. Review.
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A. Fallahi P, et al. Semin Cancer Biol. 2022 Feb;79:180-196. doi: 10.1016/j.semcancer.2020.11.013. Epub 2020 Nov 26. Semin Cancer Biol. 2022. PMID: 33249201 Review.
Several tyrosine kinase inhibitors (TKIs) are emerging as new treatments for DTC, MTC and anaplastic TC (ATC), and can induce a clinical response and stabilize the disease. Lenvatinib and sorafenib reached the approval for RAI-refractory DTC, whereas cabozantinib and vande …
Several tyrosine kinase inhibitors (TKIs) are emerging as new treatments for DTC, MTC and anaplastic TC (ATC), and can induce a clinical …
Novel targeted therapeutics for MEN2.
Redaelli S, Plaza-Menacho I, Mologni L. Redaelli S, et al. Endocr Relat Cancer. 2018 Feb;25(2):T53-T68. doi: 10.1530/ERC-17-0297. Endocr Relat Cancer. 2018. PMID: 29348306 Review.
Here, we review the rationale for RET targeting in MEN2, the use of currently available drugs and novel preclinical and clinical RET inhibitor candidates....
Here, we review the rationale for RET targeting in MEN2, the use of currently available drugs and novel preclinical and clinical RET …
Parathyroid neoplasia.
Macdonald JS. Macdonald JS. Curr Opin Oncol. 1991 Feb;3(1):139-41. doi: 10.1097/00001622-199102000-00019. Curr Opin Oncol. 1991. PMID: 1675125 Review.
Specific gene loci for multiple endocrine neoplasia type 1 and multiple endocrine neoplasia type 2a have been defined. The specificity and sensitivity of various imaging techniques for patients with these neoplasms have been quantified. ...
Specific gene loci for multiple endocrine neoplasia type 1 and multiple endocrine neoplasia type 2a have …
Pheochromocytomas in Multiple Endocrine Neoplasia Type 2.
Tsang VH, Tacon LJ, Learoyd DL, Robinson BG. Tsang VH, et al. Recent Results Cancer Res. 2015;204:157-78. doi: 10.1007/978-3-319-22542-5_7. Recent Results Cancer Res. 2015. PMID: 26494388 Review.
Compared to sporadic PC, MEN2-associated PC is more likely to be epinephine secreting and demonstrate bilateral adrenal involvement, and is less likely to be malignant. The diagnosis of PC requires clinical suspicion and biochemical testing, followed by imaging studies. .. …
Compared to sporadic PC, MEN2-associated PC is more likely to be epinephine secreting and demonstrate bilateral adrenal involvement, and is …
C-cell hyperplasia.
Guyétant S, Bléchet C, Saint-André JP. Guyétant S, et al. Ann Endocrinol (Paris). 2006 Jun;67(3):190-7. doi: 10.1016/s0003-4266(06)72585-9. Ann Endocrinol (Paris). 2006. PMID: 16840909 Review.
This article is an update on CCH physiopathology related to clinical presentation. With this combined approach, two types of CCH that differ by their physiological characteristics can be identified: neoplastic CCH and reactive (also called physiological) CCH. ...Our cli …
This article is an update on CCH physiopathology related to clinical presentation. With this combined approach, two types of CCH that …
The Hirschsprung's-multiple endocrine neoplasia connection.
Moore SW, Zaahl M. Moore SW, et al. Clinics (Sao Paulo). 2012;67 Suppl 1(Suppl 1):63-7. doi: 10.6061/clinics/2012(sup01)12. Clinics (Sao Paulo). 2012. PMID: 22584708 Free PMC article. Review.
Better understanding of the RET-620 relationship allows for a more cost-effective method of identifying those at risk by focusing rearranged during transfection gene testing to this specific area as a "hot spot". The clinical awareness of possible medullary thyroid carcino …
Better understanding of the RET-620 relationship allows for a more cost-effective method of identifying those at risk by focusing rearranged …
Multiple endocrine neoplasia.
White ML, Doherty GM. White ML, et al. Surg Oncol Clin N Am. 2008 Apr;17(2):439-59, x. doi: 10.1016/j.soc.2007.12.002. Surg Oncol Clin N Am. 2008. PMID: 18375361 Review.
Identifying new RET pathways has provided molecular targets for therapies that currently are being tested in clinical trials for locally advanced, metastatic, and recurrent medullary thyroid cancer....
Identifying new RET pathways has provided molecular targets for therapies that currently are being tested in clinical trials for loca …
Multiple endocrine neoplasia type 2.
Lodish M. Lodish M. Front Horm Res. 2013;41:16-29. doi: 10.1159/000345667. Epub 2013 Mar 19. Front Horm Res. 2013. PMID: 23652668
Multiple endocrine neoplasia type 2 (MEN2) is an autosomal-dominant cancer syndrome characterized by variable penetrance of medullary thyroid carcinoma(MTC), pheochromocytoma (PHEO), and primary hyperparathyroidism (PHPT). MEN2 consists of two clinical subtypes, MEN2A and …
Multiple endocrine neoplasia type 2 (MEN2) is an autosomal-dominant cancer syndrome characterized by variable penetrance of medullary thyroi …
Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A in children: a single centre experience.
Garcés Visier C, Espinoza Vega M, Guillén Redondo P, Ollero Fresno JC, Souto Romero H, Luis Huertas A, Espinosa Góngora R, Rico Espiñeira C, Bautista FJ, Alonso Calderón JL. Garcés Visier C, et al. J Pediatr Endocrinol Metab. 2019 Aug 27;32(8):889-893. doi: 10.1515/jpem-2019-0121. J Pediatr Endocrinol Metab. 2019. PMID: 31343983 Clinical Trial.
Background To describe the complications and long-term results in patients with multiple endocrine neoplasia type 2A (MEN 2A) syndrome in whom a prophylactic thyroidectomy was performed, in relation to the recommendations of the American Thyroid …
Background To describe the complications and long-term results in patients with multiple endocrine neoplasia type …
91 results